WeVote
Log In

Bill

Bill

A 4930

Establishes "Kidney Disease Study Commission."

2026-2027 Regular Session Introduced by Shanique Speight

Creates a dedicated Kidney Disease Study Commission to drive research on causes, disparities, and treatment access, prioritizing minority and rural underserved groups.

Introduced, Referred to Assembly Health Committee
0
WeVote Research Nonpartisan
Bill Summary · A 4930

Overview

A 4930 (NJ Assembly, Session 222) establishes the Kidney Disease Study Commission within the Department of Health. The commission’s purpose is to encourage and guide research on kidney disease with a focus on minority, rural, and underserved populations, including barriers to transplantation and treatment access. The bill requires annual reporting to the Governor and Legislature.

Main purpose and intent

  • Create a dedicated body to promote kidney disease research in New Jersey.
  • Emphasize understanding and addressing disparities in kidney disease incidence, complications, treatment, and transplantation among minority and rural/underserved communities.
  • Ensure inclusive participation in research, including clinical trials, from disproportionately affected populations.
  • Produce annual progress and findings reports to inform future initiatives and policy.

Key provisions and changes

  • Establishment and location:
    • Establishes the Kidney Disease Study Commission in the Department of Health.
  • Composition:
    • Nine members total:
    • Ex officio members: Commissioner of Health, Commissioner of Human Services, and Director of the Office of Minority and Multicultural Health (or their designees).
    • Six public members with knowledge or experience in kidney disease research or treatment:
      • Appointments: one by the Senate President; one by the Senate Minority Leader; one by the Assembly Speaker; one by the Assembly Minority Leader; two by the Governor.
  • Terms and vacancies:
    • Each appointed public member serves a three-year term.
    • Initial terms: three one-year, two two-year, and one three-year terms to diversify staggered appointments.
    • Vacancies filled in the same manner as original appointments.
  • Organization and operations:
    • Commission to organize promptly after appointments and select a chairperson from among its members.
    • Chairperson appoints a secretary (not required to be a member).
    • Members serve without compensation but may be reimbursed for necessary expenses within available funds.
    • Commission to meet as called by the chairperson and to hold public hearings at designated places.
    • Department of Health to provide necessary staff support (stenographic, clerical, professional) and may utilize staff from other state, county, or municipal agencies as needed and available.
  • Duties and focus areas (Section 2 tasks):
    • Promote and encourage development of state research on: 1) Causes of kidney disease, including socioeconomic, geographic, clinical, environmental, genetic, racial/ethnic factors, and other contributors to higher rates in minority and rural/underserved populations. 2) Causes of increased kidney disease complications in these communities, and potential clinical (e.g., treatment) and nonclinical (e.g., food security, housing, insurance access) interventions to reduce incidence. 3) Causes of lower kidney transplant rates in these communities, with relevant contributing factors. 4) Reiteration of factors contributing to lower transplant rates (duplicative phrasing in the bill; intended to emphasize). 5) Possible interventions to increase kidney transplants. 6) Treatment patterns under Medicaid (C.30:4D-1 et seq.) and private insurance that affect minority, rural, and underserved communities disproportionately affected by kidney failure.
    • In research support, actively seek inclusion of minority and rural/underserved populations as study subjects in clinical trials.
  • Reporting obligations:
    • Annual report due by January 30 each year to the Governor and the Legislature (per the equivalent requirements in P.L.1991, c.164) detailing:
    • Status of the commission’s activities.
    • Results and findings of supported research.
    • Recommendations for future initiatives or actions regarding kidney disease research.
  • Effective date:
    • The act takes effect immediately upon enactment.

Who/what would be affected

  • State government:
    • Department of Health hosts the commission and provides staff support.
    • Involvement from the Department of Human Services and the Office of Minority and Multicultural Health (via ex officio members).
  • Stakeholders and communities:
    • Minority populations, rural and underserved communities disproportionately impacted by kidney disease.
    • Kidney disease patients, potential kidney transplant recipients, and their communities.
    • Researchers and institutions conducting kidney disease studies in New Jersey.
    • Medicaid and private health insurance program participants, specifically those affected by kidney disease treatment and transplantation access.
  • Public and clinical researchers:
    • Encouragement to include minority and rural/underserved populations in clinical trials.

Procedural and timeline aspects

  • Appointment process:
    • Public members appointed by legislative leaders and the Governor, with staggered initial terms to establish continuity.
  • Meetings and hearings:
    • The chairperson determines meeting schedules and locations, including public hearings.
  • Reporting timeline:
    • Annual report due every January 30, beginning after the Commission becomes active and conducts research.
  • Resources:
    • Department of Health to provide necessary staff; the Commission can utilize staff from other state or local agencies as available.

Summary

Bill A 4930 creates the Kidney Disease Study Commission to drive research on kidney disease causes, disparities, transplantation rates, and treatment patterns, with a strong emphasis on minority and rural/underserved communities. It formalizes governance, staffing, appointment procedures, and an annual reporting requirement to inform policy and future initiatives. The commission aims to increase inclusion in clinical trials and identify actionable interventions to reduce kidney disease impact and improve access to transplants within affected populations.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.